Compare ACADIA Pharmaceuticals Inc. (ACAD) vs EPR Properties (EPR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs EPR Properties — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while EPR Properties trades at $59.55 (market cap $4.58B). The key difference: ACADIA Pharmaceuticals Inc. and EPR Properties are close in size by market cap, and EPR Properties pays a 6.22% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | EPR | |
|---|---|---|
Market Cap | $4.49B | $4.58B |
Sector | Health | Real Estate |
52-Week High | $28.06 | $61.21 |
52-Week Low | $20.06 | $48.71 |
Enterprise Value | $3.69B | $7.64B |
Dividend Yield | — | 6.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
EPR Properties trades at $59.21, up 0.19% today, with a bullish technical signal supported by moving averages. The REIT shows strong profitability with a 39.93% net income margin and consistent earnings beats, including Q1 2026 EPS of $1.26 versus $0.76 expected. Recent news highlights a $315 million Six Flags acquisition and inclusion on J.P. Morgan's July Focus List (247 Wallst, 2026-07-07).
Outlook remains positive with a consensus price target of $63.00, offering 6.4% upside. Key risks include reliance on experiential assets like theaters amid economic sensitivity, while the 6.2% dividend yield provides income support. Earnings on July 29, 2026, will be critical for validating growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →
